{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:24:15Z","timestamp":1785781455208,"version":"3.56.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["F31DK115074"],"award-info":[{"award-number":["F31DK115074"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["F31DK117550"],"award-info":[{"award-number":["F31DK117550"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK117599"],"award-info":[{"award-number":["R01DK117599"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL133011"],"award-info":[{"award-number":["R01HL133011"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL146111"],"award-info":[{"award-number":["R01HL146111"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL128714"],"award-info":[{"award-number":["R01HL128714"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA227493"],"award-info":[{"award-number":["R01CA227493"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibroblast growth factor (FGF) 21, a hormone that increases insulin sensitivity, has shown promise as a therapeutic agent to improve metabolic dysregulation. Here we report that FGF21 directly targets cardiac myocytes by binding \u03b2-klotho and FGF receptor (FGFR) 4. In combination with high glucose, FGF21 induces cardiac myocyte growth in width mediated by extracellular signal-regulated kinase 1\/2 (ERK1\/2) signaling. While short-term FGF21 elevation can be cardio-protective, we find that in type 2 diabetes (T2D) in mice, where serum FGF21 levels are elevated, FGFR4 activation induces concentric cardiac hypertrophy. As T2D patients are at risk for heart failure with preserved ejection fraction (HFpEF), we propose that induction of concentric hypertrophy by elevated FGF21-FGFR4 signaling may constitute a novel mechanism promoting T2D-associated HFpEF such that FGFR4 blockade might serve as a cardio-protective therapy in T2D. In addition, potential adverse cardiac effects of FGF21 mimetics currently in clinical trials should be investigated.<\/jats:p>","DOI":"10.1038\/s41598-022-11033-x","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T06:08:32Z","timestamp":1651730912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes"],"prefix":"10.1038","volume":"12","author":[{"given":"Christopher","family":"Yanucil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Kentrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Grabner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana C.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Czaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie","family":"Heitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Westbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R.","family":"Wende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fornoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Kapiloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Faul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"11033_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia, G., Hill, M. A. & Sowers, J. R. Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. Circ. Res. 122, 624\u2013638. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311586 (2018).","journal-title":"Circ. Res."},{"key":"11033_CR2","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1161\/01.CIR.101.19.2271","volume":"101","author":"RB Devereux","year":"2000","unstructured":"Devereux, R. B. et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101, 2271\u20132276 (2000).","journal-title":"Circulation"},{"key":"11033_CR3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.amjmed.2008.03.046","volume":"121","author":"A Aneja","year":"2008","unstructured":"Aneja, A., Tang, W. H., Bansilal, S., Garcia, M. J. & Farkouh, M. E. Diabetic cardiomyopathy: Insights into pathogenesis, diagnostic challenges, and therapeutic options. Am. J. Med. 121, 748\u2013757. https:\/\/doi.org\/10.1016\/j.amjmed.2008.03.046 (2008).","journal-title":"Am. J. Med."},{"key":"11033_CR4","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","volume":"143","author":"SS Virani","year":"2021","unstructured":"Virani, S. S. et al. Heart disease and stroke statistics-2021 update: A report from the American Heart Association. Circulation 143, e254\u2013e743. https:\/\/doi.org\/10.1161\/CIR.0000000000000950 (2021).","journal-title":"Circulation"},{"key":"11033_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-00480-6","author":"S Mishra","year":"2021","unstructured":"Mishra, S. & Kass, D. A. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. https:\/\/doi.org\/10.1038\/s41569-020-00480-6 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"11033_CR6","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1056\/NEJMe2113008","volume":"385","author":"MH Drazner","year":"2021","unstructured":"Drazner, M. H. SGLT2 inhibition in heart failure with a preserved ejection fraction\u2014A win against a formidable foe. N. Engl. J. Med. 385, 1522\u20131524. https:\/\/doi.org\/10.1056\/NEJMe2113008 (2021).","journal-title":"N. Engl. J. Med."},{"key":"11033_CR7","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng, L., Lam, K. S. L. & Xu, A. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic. Nat. Rev. Endocrinol. 16, 654\u2013667. https:\/\/doi.org\/10.1038\/s41574-020-0386-0 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"11033_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrd.2015.9","volume":"15","author":"C Degirolamo","year":"2016","unstructured":"Degirolamo, C., Sabba, C. & Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15, 51\u201369. https:\/\/doi.org\/10.1038\/nrd.2015.9 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"11033_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","volume":"78","author":"FM Fisher","year":"2016","unstructured":"Fisher, F. M. & Maratos-Flier, E. Understanding the physiology of FGF21. Annu. Rev. Physiol. 78, 223\u2013241. https:\/\/doi.org\/10.1146\/annurev-physiol-021115-105339 (2016).","journal-title":"Annu. Rev. Physiol."},{"key":"11033_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tem.2014.10.002","volume":"26","author":"BM Owen","year":"2015","unstructured":"Owen, B. M., Mangelsdorf, D. J. & Kliewer, S. A. Tissue-specific actions of the metabolic hormones FGF15\/19 and FGF21. Trends Endocrinol. Metab. 26, 22\u201329. https:\/\/doi.org\/10.1016\/j.tem.2014.10.002 (2015).","journal-title":"Trends Endocrinol. Metab."},{"key":"11033_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.diabres.2012.01.004","volume":"96","author":"SY An","year":"2012","unstructured":"An, S. Y. et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res. Clin. Pract. 96, 196\u2013203. https:\/\/doi.org\/10.1016\/j.diabres.2012.01.004 (2012).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"11033_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2265.2008.03502.x","volume":"71","author":"M Mraz","year":"2009","unstructured":"Mraz, M. et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin. Endocrinol. (Oxf.) 71, 369\u2013375. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03502.x (2009).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"11033_CR13","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.2337\/dc09-0684","volume":"32","author":"AO Chavez","year":"2009","unstructured":"Chavez, A. O. et al. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32, 1542\u20131546. https:\/\/doi.org\/10.2337\/dc09-0684 (2009).","journal-title":"Diabetes Care"},{"key":"11033_CR14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db07-1476","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang, X. et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57, 1246\u20131253. https:\/\/doi.org\/10.2337\/db07-1476 (2008).","journal-title":"Diabetes"},{"key":"11033_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fendo.2015.00133","volume":"6","author":"A Planavila","year":"2015","unstructured":"Planavila, A., Redondo-Angulo, I. & Villarroya, F. FGF21 and cardiac physiopathology. Front. Endocrinol. (Lausanne). 6, 133. https:\/\/doi.org\/10.3389\/fendo.2015.00133 (2015).","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"11033_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/jhh.2012.52","volume":"27","author":"RD Semba","year":"2013","unstructured":"Semba, R. D. et al. Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J. Hum. Hypertens. 27, 397\u2013399. https:\/\/doi.org\/10.1038\/jhh.2012.52 (2013).","journal-title":"J. Hum. Hypertens."},{"key":"11033_CR17","doi-asserted-by":"publisher","DOI":"10.1159\/000509239","author":"L Gu","year":"2020","unstructured":"Gu, L., Jiang, W., Zheng, R., Yao, Y. & Ma, G. Fibroblast growth factor 21 correlates with the prognosis of dilated cardiomyopathy. Cardiology https:\/\/doi.org\/10.1159\/000509239 (2020).","journal-title":"Cardiology"},{"key":"11033_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1475-2840-12-124","volume":"12","author":"Y Shen","year":"2013","unstructured":"Shen, Y. et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc. Diabetol. 12, 124. https:\/\/doi.org\/10.1186\/1475-2840-12-124 (2013).","journal-title":"Cardiovasc. Diabetol."},{"key":"11033_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015534","volume":"5","author":"Z Lin","year":"2010","unstructured":"Lin, Z. et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE 5, e15534. https:\/\/doi.org\/10.1371\/journal.pone.0015534 (2010).","journal-title":"PLoS ONE"},{"key":"11033_CR20","doi-asserted-by":"publisher","first-page":"738","DOI":"10.20452\/pamw.14961","volume":"129","author":"M Haberka","year":"2019","unstructured":"Haberka, M. et al. Epicardial, paracardial, and perivascular fat quantity, gene expressions, and serum cytokines in patients with coronary artery disease and diabetes. Pol. Arch Intern. Med. 129, 738\u2013746. https:\/\/doi.org\/10.20452\/pamw.14961 (2019).","journal-title":"Pol. Arch Intern. Med."},{"key":"11033_CR21","doi-asserted-by":"publisher","first-page":"11841","DOI":"10.1038\/s41598-019-48356-1","volume":"9","author":"H Sunaga","year":"2019","unstructured":"Sunaga, H. et al. Activation of cardiac AMPK-FGF21 feed-forward loop in acute myocardial infarction: Role of adrenergic overdrive and lipolysis byproducts. Sci. Rep. 9, 11841. https:\/\/doi.org\/10.1038\/s41598-019-48356-1 (2019).","journal-title":"Sci. Rep."},{"key":"11033_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cyto.2015.02.019","volume":"73","author":"X Han","year":"2015","unstructured":"Han, X. et al. Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients. Cytokine 73, 176\u2013180. https:\/\/doi.org\/10.1016\/j.cyto.2015.02.019 (2015).","journal-title":"Cytokine"},{"key":"11033_CR23","doi-asserted-by":"publisher","first-page":"33953","DOI":"10.1038\/srep33953","volume":"6","author":"RH Chou","year":"2016","unstructured":"Chou, R. H. et al. Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci. Rep. 6, 33953. https:\/\/doi.org\/10.1038\/srep33953 (2016).","journal-title":"Sci. Rep."},{"key":"11033_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008910","author":"S Sommakia","year":"2021","unstructured":"Sommakia, S. et al. FGF21 (Fibroblast Growth Factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008910 (2021).","journal-title":"Circ Heart Fail."},{"key":"11033_CR25","doi-asserted-by":"publisher","first-page":"7138776","DOI":"10.1155\/2022\/7138776","volume":"2022","author":"L Fan","year":"2022","unstructured":"Fan, L., Gu, L., Yao, Y. & Ma, G. Elevated serum fibroblast growth factor 21 is relevant to heart failure patients with reduced ejection fraction. Comput. Math. Methods Med. 2022, 7138776. https:\/\/doi.org\/10.1155\/2022\/7138776 (2022).","journal-title":"Comput. Math. Methods Med."},{"key":"11033_CR26","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/ncomms3019","volume":"4","author":"A Planavila","year":"2013","unstructured":"Planavila, A. et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat. Commun. 4, 2019. https:\/\/doi.org\/10.1038\/ncomms3019 (2013).","journal-title":"Nat. Commun."},{"key":"11033_CR27","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/srep02767","volume":"3","author":"SQ Liu","year":"2013","unstructured":"Liu, S. Q. et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci. Rep. 3, 2767. https:\/\/doi.org\/10.1038\/srep02767 (2013).","journal-title":"Sci. Rep."},{"key":"11033_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.bbrc.2015.02.081","volume":"459","author":"Y Joki","year":"2015","unstructured":"Joki, Y. et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem. Biophys. Res. Commun. 459, 124\u2013130. https:\/\/doi.org\/10.1016\/j.bbrc.2015.02.081 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"11033_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/cvr\/cvu263","volume":"106","author":"A Planavila","year":"2015","unstructured":"Planavila, A. et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc. Res. 106, 19\u201331. https:\/\/doi.org\/10.1093\/cvr\/cvu263 (2015).","journal-title":"Cardiovasc. Res."},{"key":"11033_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087102","volume":"9","author":"V Patel","year":"2014","unstructured":"Patel, V. et al. Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS ONE 9, e87102. https:\/\/doi.org\/10.1371\/journal.pone.0087102 (2014).","journal-title":"PLoS ONE"},{"key":"11033_CR31","first-page":"3677","volume":"10","author":"S Hu","year":"2018","unstructured":"Hu, S., Cao, S., Tong, Z. & Liu, J. FGF21 protects myocardial ischemia-reperfusion injury through reduction of miR-145-mediated autophagy. Am. J. Transl. Res. 10, 3677\u20133688 (2018).","journal-title":"Am. J. Transl. Res."},{"key":"11033_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.cmet.2018.06.013","volume":"28","author":"CC Ruan","year":"2018","unstructured":"Ruan, C. C. et al. A2A receptor activation attenuates hypertensive cardiac remodeling via promoting brown adipose tissue-derived FGF21. Cell Metab. 28, 476-489.e475. https:\/\/doi.org\/10.1016\/j.cmet.2018.06.013 (2018).","journal-title":"Cell Metab."},{"key":"11033_CR33","doi-asserted-by":"publisher","first-page":"19529","DOI":"10.1002\/jcb.29260","volume":"120","author":"M Sun","year":"2019","unstructured":"Sun, M. et al. Fibroblast growth factor 21 protects against pathological cardiac remodeling by modulating galectin-3 expression. J. Cell Biochem. 120, 19529\u201319540. https:\/\/doi.org\/10.1002\/jcb.29260 (2019).","journal-title":"J. Cell Biochem."},{"key":"11033_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00395-019-0768-4","volume":"115","author":"J Li","year":"2020","unstructured":"Li, J. et al. Fibroblast growth factor 21 inhibited ischemic arrhythmias via targeting miR-143\/EGR1 axis. Basic Res. Cardiol. 115, 9. https:\/\/doi.org\/10.1007\/s00395-019-0768-4 (2020).","journal-title":"Basic Res. Cardiol."},{"key":"11033_CR35","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.bbadis.2019.01.019","volume":"1241\u20131252","author":"S Li","year":"1865","unstructured":"Li, S. et al. Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1. Biochim. Biophys. Acta Mol. Basis Dis. 1241\u20131252, 2019. https:\/\/doi.org\/10.1016\/j.bbadis.2019.01.019 (1865).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"11033_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCRESAHA.110.231514","volume":"108","author":"I Kehat","year":"2011","unstructured":"Kehat, I. et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ. Res. 108, 176\u2013183. https:\/\/doi.org\/10.1161\/CIRCRESAHA.110.231514 (2011).","journal-title":"Circ. Res."},{"key":"11033_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yjmcc.2016.02.020","volume":"93","author":"CL Passariello","year":"2016","unstructured":"Passariello, C. L. et al. RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome. J. Mol. Cell. Cardiol. 93, 98\u2013105. https:\/\/doi.org\/10.1016\/j.yjmcc.2016.02.020 (2016).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"11033_CR38","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.119.044805","volume":"142","author":"J Li","year":"2020","unstructured":"Li, J. et al. Signalosome-regulated serum response factor phosphorylation determining myocyte growth in width versus length as a therapeutic target for heart failure. Circulation 142, 2138\u20132154. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044805 (2020).","journal-title":"Circulation"},{"key":"11033_CR39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","volume":"5","author":"T Inagaki","year":"2007","unstructured":"Inagaki, T. et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415\u2013425. https:\/\/doi.org\/10.1016\/j.cmet.2007.05.003 (2007).","journal-title":"Cell Metab."},{"key":"11033_CR40","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCIMAGING.109.883652","volume":"3","author":"MG Khouri","year":"2010","unstructured":"Khouri, M. G., Peshock, R. M., Ayers, C. R., de Lemos, J. A. & Drazner, M. H. A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: The Dallas heart study. Circ. Cardiovasc. Imaging 3, 164\u2013171. https:\/\/doi.org\/10.1161\/CIRCIMAGING.109.883652 (2010).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"11033_CR41","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/01.res.81.5.679","volume":"81","author":"S Corda","year":"1997","unstructured":"Corda, S. et al. Trophic effect of human pericardial fluid on adult cardiac myocytes. Differential role of fibroblast growth factor-2 and factors related to ventricular hypertrophy. Circ. Res. 81, 679\u2013687. https:\/\/doi.org\/10.1161\/01.res.81.5.679 (1997).","journal-title":"Circ. Res."},{"key":"11033_CR42","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","volume":"22","author":"A Grabner","year":"2015","unstructured":"Grabner, A. et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 22, 1020\u20131032. https:\/\/doi.org\/10.1016\/j.cmet.2015.09.002 (2015).","journal-title":"Cell Metab."},{"key":"11033_CR43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/372425a0","volume":"372","author":"Y Zhang","year":"1994","unstructured":"Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425\u2013432. https:\/\/doi.org\/10.1038\/372425a0 (1994).","journal-title":"Nature"},{"issue":"Suppl 7","key":"11033_CR44","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1038\/ijo.2008.245","volume":"32","author":"RL Leibel","year":"2008","unstructured":"Leibel, R. L. Molecular physiology of weight regulation in mice and humans. Int. J. Obes. (Lond.) 32(Suppl 7), S98-108. https:\/\/doi.org\/10.1038\/ijo.2008.245 (2008).","journal-title":"Int. J. Obes. (Lond.)"},{"key":"11033_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/en.2010-1262","volume":"153","author":"C Hale","year":"2012","unstructured":"Hale, C. et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 153, 69\u201380. https:\/\/doi.org\/10.1210\/en.2010-1262 (2012).","journal-title":"Endocrinology"},{"key":"11033_CR46","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/01.CIR.0000083716.82622.FD","volume":"108","author":"LA Barouch","year":"2003","unstructured":"Barouch, L. A., Berkowitz, D. E., Harrison, R. W., O\u2019Donnell, C. P. & Hare, J. M. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108, 754\u2013759. https:\/\/doi.org\/10.1161\/01.CIR.0000083716.82622.FD (2003).","journal-title":"Circulation"},{"key":"11033_CR47","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1681\/ASN.2009121290","volume":"21","author":"KL Hudkins","year":"2010","unstructured":"Hudkins, K. L. et al. BTBR Ob\/Ob mutant mice model progressive diabetic nephropathy. J. Am. Soc. Nephrol. 21, 1533\u20131542. https:\/\/doi.org\/10.1681\/ASN.2009121290 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"11033_CR48","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1681\/ASN.2012050445","volume":"24","author":"W Pichaiwong","year":"2013","unstructured":"Pichaiwong, W. et al. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J. Am. Soc. Nephrol. 24, 1088\u20131102. https:\/\/doi.org\/10.1681\/ASN.2012050445 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"11033_CR49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/BF00429772","volume":"14","author":"DL Coleman","year":"1978","unstructured":"Coleman, D. L. Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14, 141\u2013148. https:\/\/doi.org\/10.1007\/BF00429772 (1978).","journal-title":"Diabetologia"},{"key":"11033_CR50","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.1073\/pnas.0701600104","volume":"104","author":"Y Ogawa","year":"2007","unstructured":"Ogawa, Y. et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. USA 104, 7432\u20137437. https:\/\/doi.org\/10.1073\/pnas.0701600104 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"11033_CR51","doi-asserted-by":"publisher","first-page":"26687","DOI":"10.1074\/jbc.M704165200","volume":"282","author":"H Kurosu","year":"2007","unstructured":"Kurosu, H. et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687\u201326695. https:\/\/doi.org\/10.1074\/jbc.M704165200 (2007).","journal-title":"J. Biol. Chem."},{"key":"11033_CR52","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1074\/jbc.M109.068783","volume":"285","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J. Biol. Chem. 285, 5165\u20135170. https:\/\/doi.org\/10.1074\/jbc.M109.068783 (2010).","journal-title":"J. Biol. Chem."},{"key":"11033_CR53","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fphys.2013.00247","volume":"4","author":"N Itoh","year":"2013","unstructured":"Itoh, N. & Ohta, H. Pathophysiological roles of FGF signaling in the heart. Front. Physiol. 4, 247. https:\/\/doi.org\/10.3389\/fphys.2013.00247 (2013).","journal-title":"Front. Physiol."},{"key":"11033_CR54","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1038\/s41598-017-02068-6","volume":"7","author":"A Grabner","year":"2017","unstructured":"Grabner, A. et al. FGF23\/FGFR4-mediated left ventricular hypertrophy is reversible. Sci. Rep. 7, 1993. https:\/\/doi.org\/10.1038\/s41598-017-02068-6 (2017).","journal-title":"Sci. Rep."},{"key":"11033_CR55","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/ndt\/gfv421","volume":"31","author":"M Leifheit-Nestler","year":"2016","unstructured":"Leifheit-Nestler, M. et al. Induction of cardiac FGF23\/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol. Dial Transpl. 31, 1088\u20131099. https:\/\/doi.org\/10.1093\/ndt\/gfv421 (2016).","journal-title":"Nephrol. Dial Transpl."},{"key":"11033_CR56","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1515\/jpem-2018-0507","volume":"32","author":"Y Kutluturk","year":"2019","unstructured":"Kutluturk, Y., Akinci, A., Ozerol, I. H. & Yologlu, S. The relationship between serum FGF-23 concentration and insulin resistance, prediabetes and dyslipidemia in obese children and adolescents. J. Pediatr. Endocrinol. Metab. 32, 707\u2013714. https:\/\/doi.org\/10.1515\/jpem-2018-0507 (2019).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"11033_CR57","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1161\/01.CIR.0000127126.73759.23","volume":"109","author":"DJ Lips","year":"2004","unstructured":"Lips, D. J. et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 109, 1938\u20131941 (2004).","journal-title":"Circulation"},{"key":"11033_CR58","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.1093\/emboj\/19.23.6341","volume":"19","author":"OF Bueno","year":"2000","unstructured":"Bueno, O. F. et al. The MEK1-ERK1\/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19, 6341\u20136350. https:\/\/doi.org\/10.1093\/emboj\/19.23.6341 (2000).","journal-title":"EMBO J."},{"key":"11033_CR59","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00125-015-3630-8","volume":"58","author":"C Zhang","year":"2015","unstructured":"Zhang, C. et al. Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1\/2-dependent signalling pathway. Diabetologia 58, 1937\u20131948. https:\/\/doi.org\/10.1007\/s00125-015-3630-8 (2015).","journal-title":"Diabetologia"},{"key":"11033_CR60","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038 (2021).","journal-title":"N. Engl. J. Med."},{"key":"11033_CR61","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. 384, 117\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2030183 (2021).","journal-title":"N. Engl. J. Med."},{"key":"11033_CR62","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.115.013894","volume":"131","author":"GG Schiattarella","year":"2015","unstructured":"Schiattarella, G. G. & Hill, J. A. Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation 131, 1435\u20131447. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.013894 (2015).","journal-title":"Circulation"},{"key":"11033_CR63","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10741-011-9257-z","volume":"17","author":"I Falcao-Pires","year":"2012","unstructured":"Falcao-Pires, I. & Leite-Moreira, A. F. Diabetic cardiomyopathy: Understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail. Rev. 17, 325\u2013344. https:\/\/doi.org\/10.1007\/s10741-011-9257-z (2012).","journal-title":"Heart Fail. Rev."},{"key":"11033_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107590","volume":"214","author":"KM Levine","year":"2020","unstructured":"Levine, K. M., Ding, K., Chen, L. & Oesterreich, S. FGFR4: A promising therapeutic target for breast cancer and other solid tumors. Pharmacol. Ther. 214, 107590. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107590 (2020).","journal-title":"Pharmacol. Ther."},{"key":"11033_CR65","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1242\/dev.125.18.3615","volume":"125","author":"M Weinstein","year":"1998","unstructured":"Weinstein, M., Xu, X., Ohyama, K. & Deng, C. X. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 125, 3615\u20133623 (1998).","journal-title":"Development"},{"key":"11033_CR66","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1164\/rccm.200904-0544OC","volume":"181","author":"S Srisuma","year":"2010","unstructured":"Srisuma, S. et al. Fibroblast growth factor receptors control epithelial-mesenchymal interactions necessary for alveolar elastogenesis. Am. J. Respir. Crit. Care Med. 181, 838\u2013850. https:\/\/doi.org\/10.1164\/rccm.200904-0544OC (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"11033_CR67","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1158\/1535-7163.MCT-18-0048","volume":"18","author":"R Bartz","year":"2019","unstructured":"Bartz, R. et al. Preclinical development of U3\u20131784, a novel FGFR4 antibody against cancer, and avoidance of its on-target toxicity. Mol. Cancer Ther. 18, 1832\u20131843. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0048 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"11033_CR68","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393\u20134408. https:\/\/doi.org\/10.1172\/JCI46122 (2011).","journal-title":"J. Clin. Invest."},{"key":"11033_CR69","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/emmm.201303716","volume":"6","author":"O Andrukhova","year":"2014","unstructured":"Andrukhova, O. et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol. Med. 6, 744\u2013759. https:\/\/doi.org\/10.1002\/emmm.201303716 (2014).","journal-title":"EMBO Mol. Med."},{"key":"11033_CR70","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.yjmcc.2019.11.149","volume":"138","author":"X Han","year":"2019","unstructured":"Han, X., Cai, C., Xiao, Z. & Quarles, L. D. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice. J. Mol. Cell. Cardiol. 138, 66\u201374. https:\/\/doi.org\/10.1016\/j.yjmcc.2019.11.149 (2019).","journal-title":"J. Mol. Cell. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11033-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:48:24Z","timestamp":1669326504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11033-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11033"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11033-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.16.460632","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"29 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.F. and D.K. have served as consultants for Bayer, and C.F. also for Calico Labs. C.Y. and C.F. are inventors on two pending patents (PCT\/US2019\/049211; PCT\/US19\/49161) and they are co-founders of a startup biotech company (Alpha Young LLC). C.F. is also the CSO of Alpha Young LLC. C.F. has a patent on FGFR inhibition (European Patent No. 2723391). C.F. and A.G. received honoraria for publishing a book (\u201cFGF23\u201d, Elsevier, ISBN9780128180365). A.F. is vice-president of L&F Health LLC and the scientist co-founder and a shareholder of ZyVersa Therapeutics Inc and River 3 Renal Corp. X.L., K.S., E.C.M., J.L., I.C., B.C., K.H., D.W., A.R.W., A.S., J.M.R. and M.S.K. have no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7326"}}